Horizon Pharma Inc Company News
DUBLIN, October 06, 2023-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
DUBLIN, October 03, 2023--IRISH TAKEOVER PANEL
DUBLIN, October 02, 2023--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2023.
DUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023.
DUBLIN, September 26, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing.
FTC chair Lina Khan has her sights focused on challenging mergers & acquisitions in the healthcare and tech sectors, specifically those valued under $100 million. Khan argues that these mergers can snowball into larger monopolies when left unchecked. Senior Reporter for Yahoo Finance Anjalee Khemlani joins to breakdown Lina Khan's recent statement at the Oliver Wyman Health Innovation Summit in Chicago.
FTC Chair Lina Khan wants to help create more competition in the market and avoid monopolies.
DUBLIN, September 19, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category. This is the seventh consecutive year Horizon has been named to the list and the company’s fourth time ranking No. 1.
WALTHAM, Mass. & DUBLIN, September 13, 2023--Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human an
DUBLIN, September 06, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on September 5, 2023, Horizon’s issued ordinary share capital is comprised of 229,214,753 ordinary shares, nominal value $0.0001 per share (the "Ordinary Shares") and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary
DUBLIN, September 05, 2023--Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon.
It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics.
The Federal Trade Commission is suspending its challenge to Amgen's (AMGN) $27.8 billion bid to acquire Horizon Therapeutics (HZNP). The FTC is concerned Amgen will be able to bundle its products to a couple of Horizon's, giving it an advantage over rivals. It's a notion Amgen rejects. The FTC is pausing its challenge in hopes of reaching a settlement that would allow the deal to close. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks the story down.
DUBLIN, August 23, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. Rare disease patient groups who worked with Horizon also ranked the company first in 10 of the 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships (communications, long-term support and ease of working) and services "bey
Old Arcived News About Horizon Pharma Inc
- Brean Reiterates Buy On Horizon Pharma, Likes Crealta Deal.
- Epizyme Updates Non-Hodgkin Lymphoma Drug Trial Data.
- Horizon Buying Maker Of Gout Drug For $510 Million.
- Horizon Pharma.
- Horizon Pharma (HZNP) Earnings Report: Q4 2015 Conference Call Transcript.
- Horizon Pharma (HZNP) In A Perilous Reversal.
- Horizon Pharma (HZNP) Is Today's Dead Cat Bounce Stock.
- Horizon Pharma (HZNP) Stock Gains on Raised Guidance.
- Horizon Pharma acquires Crealta Holdings for $510 million.
- Horizon Pharma agrees to buy Crealta Holdings for $510 million in cash.
- Horizon Pharma buying Crealta for $510 million.
- Horizon Pharma PLC -- Moody's: Horizon Pharma's Crealta acquisition is credit positive.
- Horizon Pharma plc and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE(R). [at noodls] - -- (Marketwired) -- -- (: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that ...
- Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an ANDA Against PENNSAID(R) 2%. [at noodls] - DUBLIN, IRELAND -- (Marketwired) -- 12/24/14 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced ...
- HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits.
- HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securi.
- HORIZON PHARMA PLC Financials.
- Horizon Pharma plc to Acquire Crealta Holdings LLC in All Cash Acquisition. [at noodls] - -- (Marketwired) -- -- (: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that ...
- Horizon Pharma plc to Present at the 34th Annual J.P. Morgan Healthcare Conference. [at noodls] - -- (Marketwired) -- -- (: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that ...
- Horizon’s Stock Fell after It Acquired Crealta Holdings.
- Insider Trading Alert - BRT, TNAV And HZNP Traded By Insiders.
- Stock To Watch: Horizon Pharma (HZNP) In Perilous Reversal.
- Strong On High Relative Volume: Horizon Pharma (HZNP).
- The Smart Money is Hoarding Shares of These 10 Healthcare Stocks, Part 2.
- Today's Weak On High Volume Stock: Horizon Pharma (HZNP).
- Trade-Ideas: Horizon Pharma (HZNP) Is Today's Strong On High Relative Volume Stock.
- Will Horizon Pharma (HZNP) Stock Be Helped By Earnings Beat?.
- XBiotech's.
Horizon Pharma Inc Short Company Overview:
symbol changed Horizon Pharma, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The companyÂ’s products include HZT-501, which completed Phase III clinical trials for the treatment of pain, osteoarthritis, and rheumatoid arthritis; LODOTRA that completed Phase III clinical trials for rheumatoid arthritis and is in Phase IIa clinical trials for asthma; TRUNOC, a Phase I clinical trials product targeting pain-related diseases; and HZN-602, a Phase I clinical trials product for the treatment of pain and arthritis. It has strategic partnerships or licensing agreements with Merck Serono; Mundipharma Medical Company; and SkyePharma and Jagotec AG. The company was founded in 2005 and is headquartered in Northbrook, Illinois.
